company background image
GEN

Genomed Spólka Akcyjna WSE:GEN Stock Report

Last Price

zł36.00

Market Cap

zł47.6m

7D

0%

1Y

-1.6%

Updated

20 May, 2022

Data

Company Financials
GEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends0/6

GEN Stock Overview

Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland.

Genomed Spólka Akcyjna Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Genomed Spólka Akcyjna
Historical stock prices
Current Share Pricezł36.00
52 Week Highzł50.00
52 Week Lowzł30.20
Beta0.049
1 Month Change-2.70%
3 Month Change1.12%
1 Year Change-1.64%
3 Year Change73.08%
5 Year Change68.54%
Change since IPO28.57%

Recent News & Updates

Mar 03
Would Genomed Spólka Akcyjna (WSE:GEN) Be Valuable To Income Investors?

Would Genomed Spólka Akcyjna (WSE:GEN) Be Valuable To Income Investors?

Today we'll take a closer look at Genomed Spólka Akcyjna ( WSE:GEN ) from a dividend investor's perspective. Owning a...

Shareholder Returns

GENPL BiotechsPL Market
7D0%-1.7%-1.2%
1Y-1.6%-40.0%-27.0%

Return vs Industry: GEN exceeded the Polish Biotechs industry which returned -38.4% over the past year.

Return vs Market: GEN exceeded the Polish Market which returned -28.3% over the past year.

Price Volatility

Is GEN's price volatile compared to industry and market?
GEN volatility
GEN Average Weekly Movementn/a
Biotechs Industry Average Movement8.6%
Market Average Movement7.7%
10% most volatile stocks in PL Market14.7%
10% least volatile stocks in PL Market5.1%

Stable Share Price: Insufficient data to determine GEN's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine GEN's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200742Anna Boguszewska-Chachulskahttps://www.genomed.pl

Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers the analysis of mutations responsible for congenital diseases in approximately 150 genes; and next-generation sequencing technology.

Genomed Spólka Akcyjna Fundamentals Summary

How do Genomed Spólka Akcyjna's earnings and revenue compare to its market cap?
GEN fundamental statistics
Market Capzł47.57m
Earnings (TTM)zł821.55k
Revenue (TTM)zł19.90m

57.9x

P/E Ratio

2.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GEN income statement (TTM)
Revenuezł0
Cost of Revenuezł0
Gross Profitzł0
Other Expenseszł0
Earningszł0

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

May 23, 2022

Earnings per share (EPS)0.62
Gross Margin63.18%
Net Profit Margin4.13%
Debt/Equity Ratio5.2%

How did GEN perform over the long term?

See historical performance and comparison

Valuation

Is Genomed Spólka Akcyjna undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


57.9x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: GEN (PLN36) is trading above our estimate of fair value (PLN26.78)

Significantly Below Fair Value: GEN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GEN is poor value based on its PE Ratio (57.9x) compared to the Polish Biotechs industry average (41.8x).

PE vs Market: GEN is poor value based on its PE Ratio (57.9x) compared to the Polish market (10.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GEN is overvalued based on its PB Ratio (5.7x) compared to the PL Biotechs industry average (4.7x).


Future Growth

How is Genomed Spólka Akcyjna forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


42.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genomed Spólka Akcyjna has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Genomed Spólka Akcyjna performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-16.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GEN has high quality earnings.

Growing Profit Margin: GEN's current net profit margins (4.1%) are higher than last year (2.2%).


Past Earnings Growth Analysis

Earnings Trend: GEN's earnings have declined by 16.7% per year over the past 5 years.

Accelerating Growth: GEN's earnings growth over the past year (99.3%) exceeds its 5-year average (-16.7% per year).

Earnings vs Industry: GEN earnings growth over the past year (99.3%) exceeded the Biotechs industry -6.2%.


Return on Equity

High ROE: GEN's Return on Equity (9.8%) is considered low.


Financial Health

How is Genomed Spólka Akcyjna's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: GEN's short term assets (PLN8.0M) exceed its short term liabilities (PLN1.4M).

Long Term Liabilities: GEN's short term assets (PLN8.0M) exceed its long term liabilities (PLN599.5K).


Debt to Equity History and Analysis

Debt Level: GEN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if GEN's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: GEN's debt is well covered by operating cash flow (397.6%).

Interest Coverage: GEN's interest payments on its debt are well covered by EBIT (423x coverage).


Balance Sheet


Dividend

What is Genomed Spólka Akcyjna current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GEN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: GEN is not paying a notable dividend for the Polish market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GEN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Anna Boguszewska-Chachulska

no data

Tenure

Dr. Hab. Anna Boguszewska-Chachulska, Ph.D. is a Co-founder of Genomed Spólka Akcyjna and has been its Chief Executive Officer since 2013. Dr. Hab. Boguszewska-Chachulska also serves as President of the Ma...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Genomed Spólka Akcyjna's employee growth, exchange listings and data sources


Key Information

  • Name: Genomed Spólka Akcyjna
  • Ticker: GEN
  • Exchange: WSE
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł47.567m
  • Shares outstanding: 1.32m
  • Website: https://www.genomed.pl

Number of Employees


Location

  • Genomed Spólka Akcyjna
  • ul. Ponczowa 12
  • Warsaw
  • 02-971
  • Poland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/20 00:00
End of Day Share Price2022/05/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.